The London Technology Team advised LabGenius on their £35 million Series B financing. The round was led by new investor M Ventures (the strategic, corporate venture capital arm of science and technology company Merck), with participation from additional new investors Octopus Ventures and LG Corp, together with existing investors including Atomico, Kindred Capital, Lux Capital and Obvious Ventures.
LabGenius is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. LabGenius operates under a hybrid business model that involves partnering with large biotech and pharmaceutical companies in parallel with pursuing a wholly-owned therapeutic pipeline.
The Goodwin team was led by Ella Donegan, Amie Corry and Sonja Jounus.
For more details please see press release here.